

White Paper 2026

Out-of-hospital controlled medication documentation:
A compliance and patient safety imperative



Joseph Acker
Dr. Tim Makrides PhD
Leon Baranowski
Lucas Hawkes-Frost

Executive Summary

Medication safety is among the most persistent unresolved challenges in modern healthcare. The World Health Organization estimates that unsafe medication practices and medication errors cost approximately US\$42 billion each year and represent a leading source of avoidable patient harm worldwide¹. In England, avoidable adverse drug events have been estimated to cost the National Health Service £98.5 million annually, consuming more than 180,000 bed days and contributing to over 1,700 deaths². The financial weight of poor medication management is therefore not incidental to the safety argument. It is part of it.

Within this challenge, controlled medicines such as morphine, fentanyl, ketamine, lorazepam and midazolam occupy a category of their own. They are core components of emergency and urgent care, yet they are classified as high alert medicines because of their disproportionate risk of serious harm, abuse and diversion, and because their handling is governed by statute rather than by clinical policy alone. Despite this, the way many organisations govern these medicines has changed remarkably little over the last 20 years. Paper registers, manual reconciliation, basic electronic forms and retrospective audit still dominate across the health sector, ambulance services and urgent care providers, even in 2026, when the technology to do otherwise is already available.


This paper turns on a single distinction. Documentation records what happened. Assurance provides confidence in what is happening now. A handwritten register can confirm, weeks later, that a transaction was recorded. It cannot show current stock across an organisation, tie an access event to a named individual, flag an anomaly as it emerges, or produce a defensible record on demand when a regulator asks for one. The interval between an event and its discovery is precisely the interval in which loss, diversion or a compliance failure goes undetected.

That interval carries a measurable price. Regulatory action against healthcare providers for controlled substance record keeping failures has repeatedly resulted in multimillion dollar civil settlements and multiyear compliance agreements, and in several of the largest cases the deficiency identified was not clinical practice but incomplete inventories and missing records^{3,4}. Beyond penalties, unreconciled discrepancies consume supervisor and management time in investigations that frequently conclude in a record keeping problem rather than a loss, expired and unmonitored stock is written off, and clinicians spend time on manual counts that returns nothing to patient care.

The corresponding opportunity is equally measurable. Evidence from hospital automated dispensing systems consistently demonstrates reduced time spent on medication retrieval and stock counting, reduced dispensary workload for controlled drugs specifically, and improved inventory accuracy, with reported savings of several hours per unit per day in stock counting alone^{5, 6}. In an environment of constrained health budgets, a governance system that improves safety while also reducing wastage, reconciliation effort and investigation time presents a materially stronger case than one justified on safety grounds alone.

The broader question is therefore not whether paper can be replaced with digital tools. It is whether an organisation's governance system can deliver the visibility, traceability and assurance that contemporary healthcare demands, at a cost that is lower than the one it is already paying to maintain the status quo. Closing this assurance gap should be treated not as a technology upgrade but as a patient safety, regulatory risk and operational efficiency strategy, and it applies as much to the smallest single site clinic as it does to a provincial ambulance service.

Introduction and Background



Healthcare has invested heavily in safer medication systems over the past two decades. Electronic prescribing, barcode medication administration, clinical decision support and integrated electronic health records have all been introduced to reduce preventable harm by strengthening the systems within which clinicians work². These developments reflect an important shift in patient safety thinking. Rather than relying on individual vigilance and voluntary reporting, healthcare now recognises that safer outcomes are achieved through well designed systems that anticipate human fallibility and provide multiple, overlapping layers of safety and assurance.

This systems based philosophy is underpinned by the work of James Reason and the Swiss Cheese Model of organisational accidents, in which harm occurs only when weaknesses across successive layers of practice momentarily align⁷. The implication is clear. Where a single control such as a paper register is the only barrier standing between routine practice and loss, diversion or regulatory breach, the system has no depth and no redundancy.

Yet the governance of controlled medicines has evolved more slowly than almost any other part of the medication chain of custody. In many organisations it still depends on handwritten registers, end of shift counts and random audits conducted weeks or months after the transactions occurred. These methods have supported professional accountability and regulatory compliance for decades, but they were designed for a period when clinical delivery, organisational complexity and the expectations placed on governance were very different from those of today.

An important distinction must be drawn at the outset. The controlled substance record is not clinical documentation in the ordinary sense. It is a legal instrument. Where a patient care record describes what was done and why, the controlled substance register exists to account for the physical custody of a scheduled drug from acquisition to administration, waste or destruction, and it is this record that a regulator inspects. The two are related but not interchangeable, and an organisation may maintain an entirely adequate clinical record while remaining unable to satisfy its statutory obligation to account for stock. Contemporary guidance and regulation both reflect this, with professional bodies now recommending continuous, analytics supported surveillance in place of periodic audit alone⁸, and regulators requiring individualised, auditable records of every person authorised to handle controlled substances⁹.

Evidence specific to this problem in the out of hospital environment is scarce. Most of what is known about controlled substance governance failure emerges either from regulatory enforcement action, which reports the failure only after it has occurred, or from hospital pharmacy research, where automation has been studied far more thoroughly than in ambulance services or urgent care. The absence of published prevalence data should not be read as an absence of exposure. It reflects the reality that a system built on periodic manual reconciliation is poorly equipped to measure its own failures, and organisations rarely discover what a paper register did not capture until an external party asks.

Description of the Problem

Modern healthcare increasingly expects more than a record of activity for the use of controlled substances. Regulators, accreditors and clinical leaders demand that governance systems provide continuous oversight, support proactive risk management and enable emerging risks to be identified before they result in loss, diversion or patient harm. This is a meaningful shift in the philosophy of governance, from reactive to proactive, and it exposes the limits of paper-based systems.

Documentation tells us what happened. Assurance provides confidence in what is happening. A handwritten register, or a basic electronic document, can confirm retrospectively that medications were transacted. It cannot provide real time visibility of stock, flag an anomaly as it occurs, reconcile custody against administration, or reliably link every access event to a named individual. The interval between an event and its discovery is precisely the interval in which loss or diversion goes undetected.

While diversion is inherently covert, it occurs frequently and is often detected late or not at all. Periodic manual review tends to reveal a problem only long after the fact, which is why current professional guidance now recommends continuous, analytics supported surveillance rather than periodic audit alone⁸. The difficulty is compounded where controlled medicines are accessed through shared keys or pooled credentials, because the resulting record cannot tie an individual event to a named person. A shared key proves that access was authorised, but it cannot establish who opened the cabinet, and it is precisely this individual accountability that controlled substance regulation now requires⁹.

There is also a cost to ambiguity that is rarely accounted for. Most discrepancies are not diversion. They are transcription errors, missed countersignatures, unrecorded transfers and arithmetic errors, and a paper system cannot distinguish these from a genuine loss without an investigation. Every unexplained variance therefore consumes supervisory and management time and frequently concludes with the finding that the drug was never missing at all.

The assurance gap is often assumed to be a problem of scale, relevant only to large services managing high volumes of controlled medicines. In practice it affects providers of every size, though it manifests differently in each.

Out of Hospital Care and Ambulance Services

Out of hospital care is the most demanding environment for medication governance. Clinicians administer high alert medicines in uncontrolled settings, under time pressure, and frequently as single responders without a second checker present. Stock moves constantly between stations, vehicles and personnel across dispersed geographies, and custody changes hands at every shift transition. In one incident experienced by the authors, a supply of controlled substances was reported missing and, after a fruitless search of paper records, was eventually located inside an ambulance that had been sent for servicing. This was a failure of tracking rather than intent, but it consumed days of management effort and would have been reportable as a loss had it not been resolved.

Regulatory expectations are also rising. Recent reforms require ambulance services, including small providers, to maintain individualised, auditable records of every person authorised to handle controlled substances, an expectation that pooled keys and paper logs are poorly equipped to meet⁹.

Urgent Care Clinics

Urgent care clinics stock and administer controlled medicines for acute presentations, often with high patient throughput, variable staffing and clinicians who rotate between sites. The same conditions apply in general practice and small medical centres, and the observations below hold for both. Reconciliation is a manual, end of shift task competing directly with clinical demand, and the direct observation literature consistently associates task error in acute settings with interruptions, multitasking and fatigue¹⁰, the very conditions under which manual registers are least likely to be completed accurately and in real time.

The Cost of the Assurance Gap

The case for change is usually argued on safety grounds alone. In a constrained fiscal environment that argument is incomplete, because the current system is not free. Maintaining paper based controlled substance governance carries a recurring cost in regulatory exposure, management time, wasted stock and clinical hours, and that cost is largely invisible because no one measures it.

Regulatory exposure. Controlled substance record keeping is a statutory obligation, and failure to meet it attracts financial penalty independent of whether any drug was lost. Enforcement action against healthcare providers has repeatedly resulted in civil settlements in the millions of dollars, accompanied by multiyear compliance agreements that impose external audits, mandated reporting and physical security upgrades at the provider's expense^{4,9}. In one of the most cited cases, the deficiencies identified included inventory count discrepancies exceeding 20,000 units, incomplete inventories and hundreds of missing records. Those are documentation failures, not clinical ones, and a paper register is uniquely poorly placed to prevent them.

Investigation and management time. For ambulance services in particular, the most immediate saving lies in what is not spent investigating discrepancies. Every unexplained variance in a manual register triggers a process of reconstruction across shifts, vehicles and stations, and the majority of these conclude in a record keeping error rather than a loss. This effort is supervisory rather than clinical, it is rarely costed, and it scales with geographic dispersion. Where administration and waste data are captured electronically, outlier analysis can identify patterns for review directly, and services using this approach have detected real diversion through comparative monitoring that manual audit had not surfaced¹¹. A system that resolves most variances automatically converts an open-ended investigation into a closed record.

Stock, wastage and visibility. Manual systems provide no current view of holdings, which drives both overstocking and expiry. Where controlled drug stock has been managed through digital inventory control, transaction and ordering data has been used to rationalise stock lists and standardise holding levels, reducing order frequency and redistributing workload away from out of hours periods⁶. Comparable work in tightly controlled product categories has demonstrated improved stock control alongside faster resolution of discrepancies¹².

Clinician and administrative time. The efficiency evidence from hospital automated dispensing is substantial. A scoping review of the field reported nursing time gains of up to 14.7 hours per day across three intensive care units, 66 minutes saved per ward per day on medication administration, and 6 hours saved daily on stock inventory counting following implementation¹³. Time and motion work has recorded medication retrieval times halving and the number of storage locations visited per patient falling by around 40 per cent⁵. These figures come from inpatient environments and do not transfer directly to a vehicle or a clinic cabinet, but the mechanism is the same: time returned by removing manual counting and searching.

Taken together, the position is straightforward. The assurance gap is not only a patient safety and compliance risk. It is an ongoing operating cost, and one that a business case can quantify.

Possible Solutions

A digital controlled medication management system reframes governance from a retrospective record into a continuous assurance capability, adding layers of control where paper or basic electronic documents offer only one. The core capabilities that distinguish assurance from documentation are:

- Real time visibility and reconciliation of stock, administration and waste, so that discrepancies surface immediately rather than at the next scheduled count.
- Individual accountability through authenticated, time stamped access that links every event to a named clinician and removes the ambiguity of shared keys and cabinets.
- Complete chain of custody that tracks each unit from delivery through administration, waste or destruction across stations, vehicles and sites.
- Proactive risk detection that flags anomalous patterns for review, supporting a preventive model rather than a reactive one, consistent with current guidance on continuous surveillance⁸.
- Audit and regulatory readiness, with defensible, tamper evident records available on demand rather than reconstructed under inspection pressure.

For providers operating across multiple locations, consolidation is the decisive gain. A centralised system replaces many isolated registers with a single record updated in real time, so that stock, administration, waste and access are visible across the whole organisation rather than trapped in individual books. It standardises practice at every site, ties each clinician's activity to them wherever they work, and gives governance leaders timely oversight of the entire estate without a physical visit to each cabinet. For a multisite provider, this is not simply an efficiency. It is what makes organisational assurance possible at all.

The operational and financial return

These capabilities are also where the savings identified in the preceding section are realised. Automated reconciliation removes the routine manual count and resolves the majority of variances at the point they occur, so that supervisory investigation is reserved for the small number of events that warrant it. Consumption and expiry data enable stock levels to be set against actual use rather than estimate, reducing both overstocking and write off. Access and administration records that are already structured make regulatory reporting a query rather than a reconstruction exercise. Each of these returns time to operational leaders and clinicians, and each is measurable, which matters when a proposal must compete against other proposals on a constrained budget.

Critically, none of this depends on organisational scale. The same architecture that gives a national service oversight across hundreds of vehicles can give a single clinic the redundancy, traceability and independent oversight that a paper register cannot provide, and it does so without adding to clinical workload. The distinction is not between large and small providers but between those whose governance can demonstrate what is happening now and those who can only describe what happened.

Recommendations

The foundational contribution of paper-based registers should be acknowledged. They established professional accountability and satisfied regulatory expectation for decades. But the legal and compliance obligations now placed on organisations, and the standard of governance expected of them, have moved beyond what those systems were ever designed to deliver.

The decisive question is no longer whether an organisation can replace paper with digital tools. It is whether its governance provides the visibility, traceability and assurance that patients and regulators expect in today's modern era, and whether it can afford to continue paying the cost of not having them.

We recommend that providers handling controlled medicines:

1. **Assess the current state honestly.** Establish whether the organisation can, today and without reconstruction, identify what stock it holds, where it is, who last accessed it and whether the record reconciles. Where the answer requires a physical count or a search of paper, the assurance gap is present.
2. **Quantify what the status quo costs.** Estimate supervisory hours spent investigating discrepancies, the value of stock written off at expiry, and the time clinicians spend on manual counting and reconciliation. These figures are usually unmeasured, and they are what convert a safety argument into a business case.
3. **Establish individual accountability as a minimum standard.** Shared keys and pooled credentials cannot satisfy contemporary regulatory expectations of individualised, auditable records, and should be treated as a governance deficiency rather than an operational convenience⁹.
4. **Move from periodic audit to continuous surveillance.** Adopt systems capable of flagging anomalous patterns as they emerge, consistent with current professional guidance, rather than relying on scheduled review to detect problems retrospectively⁸.
5. **Consolidate records across sites and vehicles.** Where an organisation operates from more than one location, a single connected record is a precondition of organisational oversight, not an enhancement to it.
6. **Treat implementation as a governance programme, not a procurement.** The evidence from hospital automation is clear that benefits depend on alignment with existing workflow, adequate training and local support, and that poorly configured systems can introduce their own inefficiencies¹³.

This applies across the entire healthcare landscape. From the single crewed ambulance to the busy urgent care clinic, the assurance gap is real, the consequences of leaving it open are measured in patient harm and regulatory exposure, and the cost of closing it is lower than the cost of maintaining it.

References

1. World Health Organisation. Medication without harm. World Health Organization; 2017.
2. Elliott RA, Camacho E, Jankovic D, Sculpher MJ, Faria R. Economic analysis of the prevalence and clinical and economic burden of medication error in England. *BMJ Quality & Safety*. 2021;30(2):96-105.
3. U.S. Attorney's Office. MGH to Pay \$2.3 Million to Resolve Drug Diversion Allegations. Press Release. Boston, MA: U.S. Department of Justice; 2015/09/28.
4. US Drug Enforcement Agency. United States Reaches \$4.17 Million Civil Settlement and Three-Year Compliance Agreement with West Virginia University Health System Over Controlled Substance Violations. Press Release. U.S. Department of Justice; 2026/07/13.
5. Jeffrey E, Walsh Á, Hague J, Lai K. Comparing nursing medication rounds before and after implementation of automated dispensing cabinets: A time and motion study. *Explor Res Clin Soc Pharm*. 2024;16:100504.
6. Walsh Á, Jeffrey E, Lai K. Streamlining and improving controlled drug dispensary workload in a London teaching hospital following the implementation of automated dispensing cabinets on wards: A quality improvement project. *Explor Res Clin Soc Pharm*. 2025;18:100594.
7. Reason J. Human error: models and management. *Bmj*. 2000;320(7237):768-70.
8. Clark J, Fera T, Fortier C, Gullickson K, Hays A, Murdaugh L, et al. ASHP guidelines on preventing diversion of controlled substances. *American Journal of Health-System Pharmacy*. 2022;79(24):2279-306.
9. US Drug Enforcement Agency. Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017. In: Justice USDo, editor. Federal Register. Washington, DC: Office of the Federal Register, National Archives and Records Administration; 2026. p. 5213-66.
10. Westbrook JI, Raban MZ, Walter SR, Douglas H. Task errors by emergency physicians are associated with interruptions, multitasking, fatigue and working memory capacity: a prospective, direct observation study. *BMJ quality & safety*. 2018;27(8):655-63.
11. Richmond NJ, Gleason W. Best Practices for Controlled Substance Monitoring. *JEMS: Journal of Emergency Medical Services*. 2017.
12. Pinfield A, Lai K, Jones S. Measuring the impact of automated dispensing cabinets implementation on data and inventory management of human normal immunoglobulin in an acute teaching hospital: A pre- and post-intervention study. *Explor Res Clin Soc Pharm*. 2024;16:100516.
13. Jung YY, Walsh Á, Patel J, Lai K. Benefits and challenges associated with implementation and ongoing use of automated dispensing cabinet for medicines: A scoping review. *Explor Res Clin Soc Pharm*. 2025;18:100599.

